Solid-State Chemistry: A Technical Forum - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Solid-State Chemistry: A Technical Forum
Leading experts share insight on polymorphism and crystallization.


Pharmaceutical Technology
Volume 33, Issue 12, pp. 34-35, 65

References

1. ICH, Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances (1999).

2. H.G. Brittain, Ed., Polymorphism in Pharmaceutical Solids (2nd edition, Informa Healthcare, London).

3. J. Haleblian and W. McCrone, J. Pharm. Sci., 58 (58), 911–929 (1969).

4. T.L. Threlfall, Analyst, 120 (10) 2435–2460 (1995).

5. D. Singhal D and W. Curatolo, Adv. Drug Delivery Rev. 56 (5) 335–347 (2004).

6. S.L. Price, Acc. Chem. Res. 42 (1) 117–126 (2009).

7. M.A. Neumann and M.A. Perrin, J. Phys. Chem. B, 109 (32), 15531–15541 (2005).

8. M.A. Neumann, J. Phys. Chem. B, 112 (32), 9810–9829 (2008).

9. M.A. Neumann, F.J.J. Leusen, and J. Kendrick, Angew. Chem. Int. Ed. 47 (13), 2427–2430 (2008).

10. G.M. Day et al., Acta Cryst. B 65 (2) 107–125 (2009).

11. S.R.Chemburkar et al., Org. Process Res. Dev. 4 (5), 413–417 (2000).

12. Y. Kobayashi et al., "Int. J. Pharm 193 (2), 137–146 (2000).

13. J. Aaltonen et al., Eur. J. Pharm. Biopharm. 71 (1), 23–37 (2009).

For additional insight on screening strategies in solid-state chemistry, see http://pharmtech.findpharma.com/pharmtech/Ingredients/Polymorph-Screening-Strategies-A-QampA-with-Jan-Ol/ArticleStandard/Article/detail/647428.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here